• Je něco špatně v tomto záznamu ?

Immunomodulation with β-glucan from Pleurotus ostreatus in patients with endocrine-dependent breast cancer

J. Spacek, M. Vocka, E. Zavadova, B. Konopasek, L. Petruzelka

. 2022 ; 14 (1) : 31-40. [pub] 20211117

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22011486

Aim: To evaluate the effect of pleuran (β-glucan from Pleurotus ostreatus) administration on the immune profile of patients with endocrine-dependent breast cancer (clinical stages I-II) in clinical and imaging remission. Methodology: Antitumor cellular immunity (CD19+, CD3+, CD4+ and CD8+ T lymphocytes and natural killer cells) of 195 patients (49 in the pleuran group and 146 in the control group) was measured by flow cytometry. Results: We observed a significant increase in the absolute number of CD3+, CD19+, CD4+ and CD8+ T lymphocytes in the pleuran group compared with the control group. Conclusion: Our results suggest potential benefit of continuous pleuran administration on immune rehabilitation of cellular antitumor immunity and better prognosis in breast cancer patients in remission.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011486
003      
CZ-PrNML
005      
20220506130846.0
007      
ta
008      
220425s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.2217/imt-2021-0069 $2 doi
035    __
$a (PubMed)34784798
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Spacek, Jan $u Department of Oncology, First Faculty of Medicine, Charles University & General University Hospital in Prague, U Nemocnice 2, Praha 2, 128 08, Czech Republic $1 https://orcid.org/000000019703209X $7 xx0181883
245    10
$a Immunomodulation with β-glucan from Pleurotus ostreatus in patients with endocrine-dependent breast cancer / $c J. Spacek, M. Vocka, E. Zavadova, B. Konopasek, L. Petruzelka
520    9_
$a Aim: To evaluate the effect of pleuran (β-glucan from Pleurotus ostreatus) administration on the immune profile of patients with endocrine-dependent breast cancer (clinical stages I-II) in clinical and imaging remission. Methodology: Antitumor cellular immunity (CD19+, CD3+, CD4+ and CD8+ T lymphocytes and natural killer cells) of 195 patients (49 in the pleuran group and 146 in the control group) was measured by flow cytometry. Results: We observed a significant increase in the absolute number of CD3+, CD19+, CD4+ and CD8+ T lymphocytes in the pleuran group compared with the control group. Conclusion: Our results suggest potential benefit of continuous pleuran administration on immune rehabilitation of cellular antitumor immunity and better prognosis in breast cancer patients in remission.
650    _2
$a nádory prsu $x imunologie $7 D001943
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunomodulace $x imunologie $7 D056747
650    _2
$a lidé středního věku $7 D008875
650    _2
$a Pleurotus $x imunologie $7 D020076
650    _2
$a beta-glukany $x imunologie $7 D047071
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Vocka, Michal $u Department of Oncology, First Faculty of Medicine, Charles University & General University Hospital in Prague, U Nemocnice 2, Praha 2, 128 08, Czech Republic
700    1_
$a Zavadova, Eva $u Department of Oncology, First Faculty of Medicine, Charles University & General University Hospital in Prague, U Nemocnice 2, Praha 2, 128 08, Czech Republic
700    1_
$a Konopasek, Bohuslav $u Department of Oncology, First Faculty of Medicine, Charles University & General University Hospital in Prague, U Nemocnice 2, Praha 2, 128 08, Czech Republic
700    1_
$a Petruzelka, Lubos $u Department of Oncology, First Faculty of Medicine, Charles University & General University Hospital in Prague, U Nemocnice 2, Praha 2, 128 08, Czech Republic
773    0_
$w MED00175821 $t Immunotherapy $x 1750-7448 $g Roč. 14, č. 1 (2022), s. 31-40
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34784798 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130838 $b ABA008
999    __
$a ok $b bmc $g 1789206 $s 1162684
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 14 $c 1 $d 31-40 $e 20211117 $i 1750-7448 $m Immunotherapy $n Immunotherapy $x MED00175821
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace